Management Old

David Westberg has many years of experience in the pharmaceutical industry, including roles at Pharmacia, Pharmacia-UpJohn and Orexo. He has worked as a global project manager for development projects and was Head of Product Development (Pharmaceutical and Analytical Development) at Pharmacia amongst many other roles. David was also the main project manager who was responsible for taking two major Orexo products (Edluar and Zubsolv) from the early development phase through formulation development and clinical studies and onto registration and market approval with the FDA in the US.

David has also worked as a consultant on a range of business development projects in the pharmaceutical industry.

Mårten Rooth is a co-founder of Nanexa. He has extensive experience in Atomic Layer Deposition (ALD), with several published scientific articles in the field.

Björn Svanström has extensive experience in economics, finance and the capital market, from roles in Corporate Finance at SEB Enskilda, Group Controller at Teleca AB, CEO of Praktikertjänst’s investment company Praktikerinvest and in recent years as CFO in development housing.

Anders Johansson is a co-founder of Nanexa. He has previous experience of working as a patent consultant at the patent office Bjerkéns KB

Mikael Asp has more than 30 years’ experience in development, Quality Assurance and manufacturing of pharmaceuticals. Mikael has worked at Pharmacia, Fresenius-Kabi, Pfizer, Oasmia and others, as Production manager, Quality manager, CTO and CEO.

Dr Gårdmark has extensive experience in product development of medicines. She has more than 10 years’ experience from leading roles within the Medical Products Agency. As Director of Licensing at the Medical Products Agency, she was responsible for decisions related to drug approvals and decisions on clinical trials and scientific advice. She was also active in the development of guidelines and legislative issues. In addition to this, Dr. Gårdmark has more than 10 years’ experience from senior roles in both big pharma and small pharmaceutical companies, primarily in the area of strategic regulatory issues in connection with product development projects, due diligence activities and advisory meetings with the FDA and EMA. Her main focus has been in preclinical and clinical development.

Sven has broad commercial and clinical experience from the international pharmaceutical industry, based on leading positions within Pharmacia, AstraZeneca and Orexo. Sven’s strength is to provide strategic commercial support in life science projects under development, preparing the projects for successful licensing or launch. In addition, Sven has several years’ experience in business development and has successfully negotiated and completed several license agreements.

Otto Skolling has worked for more than 25 years in the pharmaceutical industry, primarily in business development and financing, but also product development. Among other roles, Otto has worked at PharmaciaUpJohn (Project Director), Novozymes (Director Product Pipeline, Business Development & Director M&S Biopharmaceutical ingredients), Karolinska Development (Vice President Business Development / Portfolio Management). Otto also has extensive experience from board work from start-up companies in the pharmaceutical industry

Dr Luhr has more than 15 years’ experience from a number of leading positions in the global pharmaceutical industry, at companies such as Pfizer, Actelion and Celgene. Dr. Luhr has held positions as Medical Director in Asia and in China with a focus on Medical Affairs, Medical marketing and pharmacovigilance and built up Celgenes’ medical organization in China. During his time at Actelion, the responsibility for regulatory affairs was also within his area of ​​responsibility, in addition to Medical Affairs.